Ramiven® 150mg
Brand Name: Ramiven® 150mg
Composition: Abemaciclib150mg
Manufacturer: Eli Lilly and Company
Product Description
Medical Info
Ramiven® 150mg is an advanced targeted prescription oncology medication containing Abemaciclib, a potent cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Developed by Eli Lilly, these film-coated tablets are primarily indicated for patients diagnosed with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. By selectively blocking proteins that drive uncontrolled cell division, the therapy halts cancer cell multiplication and helps shrink tumor tissues. Taken orally with or without food, Ramiven® is prescribed either as a standalone treatment or combined with endocrine therapies under strict specialist guidance. Regular clinical monitoring of blood counts is advised during treatment.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
